A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Completed · Phase 1

Conditions studied: Breast Cancer

In brief

This open-label, parallel group study will evaluate the pharmacokinetics and safety of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and normal or reduced hepatic function. Patients will receive trastuzumab emtansine intravenously on Day 1 of each 3-week cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Key facts

Study ID

NCT01513083

Run by

Hoffmann-La Roche

People needed

28

Starts

2012-02-01

Expected to finish

2014-09-01

Last updated by the study team

2016-11-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients, >/= 18 years of age
• Histologically or cytologically documented invasive metastatic breast cancer
• Human epidermal growth factor receptor 2 (HER2) -positive disease
• Adequate bone marrow and organ function (other than hepatic dysfunction allowed by protocol)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Left ventricular ejection fraction >/=50%
• Normal hepatic function, or mild to moderate hepatic impairment (Child-Pugh Class A or B)

You may not qualify if…

• History of Grade >/=3 infusion reaction, hypersensitivity reaction, or pneumonitis in response to trastuzumab
• Investigational therapy or any other anticancer therapy </=28 days before first study treatment
• Previous treatment with trastuzumab emtansine
• Brain metastases that are untreated or symptomatic or require therapy to control symptoms or any radiation, surgery or other therapy to control symptoms from brain metastases within 1 month of the first study treatment
• History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those mentioned above
• Current peripheral neuropathy of Grade >/=2
• Child-Pugh Class C hepatic impairment
• Encephalopathy >/= Grade 2
• For patients with normal hepatic function: history of drug or alcohol addiction or history of hepatitis B and/or hepatitis C
• Active hepatitis A, B and/or C
• Current unstable ventricular arrhythmia requiring treatment
• History of symptomatic CHF (NYHA Classes II-IV)
• History of myocardial infarction or unstable angina within 6 months of enrollment
• History of a decrease in LVEF to<40% or symptomatic CHF with previous trastuzumab treatment
• Pregnant or lactating women
• Known HIV infection

Where it is running

• Study site — Fort Myers, Florida, United States
• Study site — Detroit, Michigan, United States
• Study site — Portland, Oregon, United States
• Study site — Nashville, Tennessee, United States
• Study site — Ottawa, Ontario, Canada
• Study site — Toronto, Ontario, Canada
• Study site — Marseille, France
• Study site — Paris, France
• Study site — Toulouse, France
• Study site — Catanzaro, Calabria, Italy
• Study site — Udine, Friuli Venezia Giulia, Italy
• Study site — Barcelona, Barcelona, Spain
• Study site — Madrid, Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.